Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Kate Zhong"'
Autor:
Dawn C. Matthews, Jefferson W. Kinney, Aaron Ritter, Randolph D. Andrews, Erin N. Toledano Strom, Ana S. Lukic, Lauren N. Koenig, Carolyn Revta, Howard M. Fillit, Kate Zhong, Babak Tousi, James B. Leverenz, Howard H. Feldman, Jeffrey Cummings
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract INTRODUCTION The “A/T/N” (amyloid/tau/neurodegeneration) framework provides a biological basis for Alzheimer's disease (AD) diagnosis and can encompass additional changes such as inflammation (“I”). A spectrum of T/N/I imaging and pl
Externí odkaz:
https://doaj.org/article/928ea7d24f9142e28dbc79c4984a4006
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 2, Pp n/a-n/a (2024)
Abstract INTRODUCTION New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. METHODS We interrogated clinicaltrials.gov including all clinical tr
Externí odkaz:
https://doaj.org/article/125a19a3ab2341c8adc5e8993673bed6
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 2, Pp n/a-n/a (2023)
Abstract Introduction Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. Methods We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD
Externí odkaz:
https://doaj.org/article/ecd89b237a8d4c8382a46b97170815de
Autor:
Jeffrey Cummings, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Fonseca, Kazem Taghva
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical tri
Externí odkaz:
https://doaj.org/article/324c0a0701fd4c1ba4d0d977162257a7
Autor:
Dawn C. Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana S. Lukic, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard H. Feldman, Jeffrey Cummings
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Background A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO‐B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD
Externí odkaz:
https://doaj.org/article/bbc8b6f10a0e49f7b69e4a8a1eb7ceb0
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. Methods We int
Externí odkaz:
https://doaj.org/article/c968e52a0f3f43a8a31cb7e2c51028b6
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of
Externí odkaz:
https://doaj.org/article/236dcd6908fc4ced9c8e3e53c58e02d3
Autor:
Mary Sano, Jeffrey Cummings, Stefanie Auer, Sverre Bergh, Corinne E. Fischer, Debby Gerritsen, George Grossberg, Zahinoor Ismail, Krista Lanctôt, Maria I. Lapid, Jacobo Mintzer, Rebecca Palm, Paul B. Rosenberg, Michael Splaine, Kate Zhong, Carolyn W. Zhu
Publikováno v:
International Psychogeriatrics. :1-13
Background: The International Psychogeriatric Association (IPA) published a provisional consensus definition of agitation in cognitive disorders in 2015. As proposed by the original work group, we summarize the use and validation of criteria in order
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebfdf0c4d2d9bd2d4fa803a627520d99
https://doi.org/10.1017/s1041610222001041
https://doi.org/10.1017/s1041610222001041
Autor:
Jeffrey Cummings, Mary Sano, Stefanie Auer, Sverre Bergh, Corinne E. Fischer, Debby Gerritsen, George Grossberg, Zahinoor Ismail, Krista Lanctôt, Maria I. Lapid, Jacobo Mintzer, Rebecca Palm, Paul B. Rosenberg, Michael Splaine, Kate Zhong, Carolyn W. Zhu
Publikováno v:
International Psychogeriatrics. :1-12
Objectives To develop an agitation reduction and prevention algorithm is intended to guide implementation of the definition of agitation developed by the International Psychogeriatric Association (IPA) Design: Review of literature on treatment guidel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7aa6c0fb057e0fcd250dbdfb0e0ed80b
https://doi.org/10.1017/s104161022200103x
https://doi.org/10.1017/s104161022200103x
Autor:
Kate Zhong
Publikováno v:
Alzheimer's & Dementia. 17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa482d7ee1a997097acaf8cf7661a469
https://doi.org/10.1002/alz.056719
https://doi.org/10.1002/alz.056719